Drugs / Teripalimab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06721286 | Nov 2024 → Dec 2026 expected | intrahepatic cholangiocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03985670 | Jul 2019 → Apr 2021 | esophageal squamous cell carcinoma | Henan Cancer Hospital | Unknown | Missed primary |
| Phase 2 | NCT04177875 | May 2019 → Apr 2021 | esophageal cancer | Tongji Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Teripalimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06721286 ↗ |
| Action | Inhibit | “The PD-1 antibody, teripalimab, is an immunological checkpoint inhibitor” NCT03985670 ↗ |
| Modality | Monoclonal antibody | “The PD-1 antibody, teripalimab, is an immunological checkpoint inhibitor” NCT03985670 ↗ |
| Route | Intravenous | “240mg intravenous injection” NCT06721286 ↗ |